Ipsen announces 13 posters and 1 oral presentation at the 2018 ASCO Gastrointestinal Symposium

Ipsen to co-host financial community briefing to discuss data presented at the 2018 American Society of Clinical Oncology Gastrointestinal Cancers Symposium

 

Paris (France), 15 January 2018 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced that irinotecan liposome injection (Onivyde®), cabozantinib (Cabometyx®), lanreotide (Somatuline® Autogel® / Depot®), and telotristat ethyl (Xermelo®) are the subject of 11 posters, along with  2 others focusing on patients living with neuroendocrine tumors, at the 2018 American Society of Clinical Oncology’s Gastrointestinal Cancers Symposium (ASCO-GI), January 18-20, 2018 in San Francisco (CA, USA). In addition, cabozantinib (Cabometyx®) will be featured in one oral abstract session:

 

Oral Abstract Session B – Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract Friday, January 19: 2:15 PM-3:45 PM

  • Abstract 207:

Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: results from the randomized phase 3 CELESTIAL trial.

First Author: Ghassan Abou-Alfa, MD

“Ipsen has a strong presence in oncology at ASCO-GI 2018 with 13 posters dealing with clinical outcomes in pancreatic cancer, advanced hepatocellular carcinoma, neuroendocrine tumors and carcinoid syndrome. We and Exelixis, our partner, are excited to announce that the results of the pivotal Phase 3 CELESTIAL Trial of Cabozantinib in Previously Treated Advanced Hepatocellular Carcinoma will be shared for the first time with the medical community as a  late breaking presentation, on January 19th,”  said Alexandre Lebeaut, MD, Executive Vice-President, R&D, Chief Scientific Officer, Ipsen.

 

2 poster sessions (poster session B and poster session C) with 7 abstracts/posters featuring nal-IRI / liposomal irinotecan (ONIVYDE®) :

 

Poster Session B Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Poster Display Session, Friday, January 19: 11:30 AM-1:00 PM and 5:30 PM-6:30 PM

  • BOARD F20 – (Abstract 335)

Deposition characteristics and resulting DNA damage patterns of liposomal irinotecan (nal-IRI) in pancreatic cancer xenografts.

First Author: Shannon Leonard

 

  • BOARD H16 – (Abstract 379)

Subgroup analysis by baseline pain intensity (BPI) and analgesic use (BAU) in NAPOLI-1: A phase III study of liposomal irinotecan (nal IRI)±5-fluorouracil/ leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy.

First Author: Teresa Macarulla, MD, PhD

 

  • BOARD J2 – (Abstract 388)

Dose modifications of liposomal irinotecan (nal-IRI) + 5-fluorouracil/leucovorin (5-FU/LV) in NAPOLI-1: Impact on efficacy.

First Author: Andrea Wang-Gillam, MD, PhD

 

  • BOARD K3 – (Abstract 410)

Subgroup analysis by baseline (BL) weight-associated parameters: A phase III study of liposomal irinotecan (nal IRI)±5 fluorouracil/leucovorin (5 FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based (gem) therapy.

First Author: Teresa Macarulla, MD, PhD

 

  • BOARD M6 – (Abstract 459)

Nomogram for predicting overall survival (OS) in patients (pts) treated with liposomal irinotecan (nal-IRI) ± 5-fluorouracil/leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy in NAPOLI-1.
First Author: Andrea Wang-Gillam, MD, PhD

 

  • BOARD M7 – (Abstract 460)

Subgroup analysis by measurable metastatic lesion (ML) number and selected lesion locations (LL) at baseline (BL) in NAPOLI 1: A phase III study of liposomal irinotecan (nal-IRI)±5 fluorouracil/leucovorin (5 FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy.
First Author: Jens Siveke, Prof. Dr. med.

 

 

Poster Session C Cancers of the Colon, Rectum, and Anus

Poster Session Display, Saturday, January 20: 7:00 AM-7:55 AM and 11:30 AM-1:00 PM 

  • BOARD G24 – (Abstract 711)

Influence of liposomal irinotecan (nal-IRI) and non-liposomal irinotecan, alone and in combination, on tumor growth and angiogenesis in colorectal cancer (CRC) models.
First Author: Annette Larsen, DVM, PhD

 

Cabozantinib (Cabometyx®) is featured in 2 sessions:

 

Oral Abstract Session B – Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract Friday, January 19: 2:15 PM-3:45 PM

  • Abstract 207:

Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: results from the randomized phase 3 CELESTIAL trial.

First Author: Ghassan Abou-Alfa, MD

Poster Session B – Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

 

Poster Session Display, Friday, January 19: 11:30 AM-1:00 PM and 5:30 PM-6:30 PM

  • BOARD A4 – (Abstract 207)

Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: results from the randomized phase 3 CELESTIAL trial.

First Author: Ghassan Abou-Alfa, MD

 

Lanreotide (Somatuline® Autogel® / Depot®) is featured in 1 poster session:

 

Poster Session B – Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Poster Session Display, Friday, January 19: 11:30 AM-1:00 PM and 5:30 PM-6:30 PM

  • BOARD G8 – (Abstract 347)

Lanreotide for the prolonged control of carcinoid syndrome (CS) in somatostatin analog (SSA)-naïve or experienced patients.

First Author: Edward Wolin, MD

 

Neuroendocrine tumors clinical research is featured in 1 poster session:

 

Poster Session B – Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Poster Session Display, Friday, January 19: 11:30 AM-1:00 PM and 5:30 PM-6:30 PM

  • BOARD G20 – (Abstract 359)
    Living with neuroendocrine tumors: Assessing quality of life (QoL) through a mobile application.
    First Author: Jared Adams, MD, PhD

 

  • BOARD E8 – (Abstract 299)
    Physical, emotional, and informational challenges of patients living with neuroendocrine tumors in the United States: Understanding their unmet needs.
    First Author: Grace Goldstein

 

 

Telotristat ethyl (Xermelo®) is featured in 1 poster session

 

Poster Session B – Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Poster session, Friday, January 19: 11:30 AM-1:00 PM and 5:30 PM-6:30 PM

  • BOARD J9 – (Abstract 395)
    Time to sustained improvement in bowel movement frequency with telotristat ethyl: Analysis of the phase III TELECAST study.
    First Author: Joseph Dillon

 

Nota bene: Approved indications for products vary by country and not all indications are available in every country. The product safety and efficacy profiles have not yet been established outside the approved indications.  

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved. - 2019